CollPlant Expands the Distribution of its VergenixSTR Product in Europe
MWN-AI** Summary
CollPlant Biotechnologies, a company focused on regenerative and aesthetic medicine, has announced the expansion of its Vergenix™ STR product distribution in Europe with a new agreement in Poland. Vergenix™ STR, which utilizes the company’s rhCollagen technology, is designed to treat tendinopathy by promoting healing in tendon injuries. This product acts as a soft tissue repair matrix that integrates with platelet-rich plasma (PRP), forming a scaffolding that enhances healing through a localized and sustained release of growth factors at the injury site.
The Vergenix™ STR product targets a range of tendon injuries, including lateral epicondylitis (tennis elbow), rotator cuff injuries, and Achilles tendon issues. Yehiel Tal, CollPlant's CEO, voiced enthusiasm about the expanded distribution, highlighting the significant market potential in Europe and the Asia-Pacific regions. The company plans to deliver the first shipment to its Polish distributor by the end of the current year and aims to broaden its distribution to additional markets.
CollPlant’s innovative approach harnesses recombinant human collagen, produced using its proprietary plant-based technology, positioning the company at the forefront of medical solutions centered around tissue repair and aesthetics. The collaboration with Allergan, a leader in the dermal filler market, signifies further advancement in commercializing its products.
In a market driven by the increasing demand for effective treatment solutions, CollPlant’s focus on a differentiated therapeutic approach through Vergenix™ STR presents promising opportunities for growth. As the company moves forward, the successful rollout of this product could enhance its market presence and support broader acceptance of its unique rhCollagen-based offerings in the medical field.
MWN-AI** Analysis
CollPlant Biotechnologies’ recent expansion of its Vergenix™ STR product distribution in Europe signals a strategic move that could enhance its market positioning and revenue potential. Vergenix™ STR, designed for treating tendon injuries through its unique combination of recombinant collagen and platelet-rich plasma (PRP), represents a significant innovation in regenerative medicine. This product offers a solution for prevalent conditions such as lateral epicondylitis and rotator cuff injuries, which can result in high healthcare costs and patient dissatisfaction due to limited recovery options.
From an investment perspective, the decision to broaden distribution networks, particularly by establishing a foothold in Poland, reflects confidence in the product's market potential. As Europe continues to invest in advanced medical procedures and regenerative health technologies, CollPlant is poised to leverage this trend. The partnership with local distributors is essential for navigating regulatory landscapes and ensuring product accessibility, which can enhance sales traction.
Investors should watch for key performance indicators such as first shipment timelines and market penetration rates. As the company ramps up its distribution, early sales figures for Vergenix™ STR could serve as critical benchmarks for sustained growth. Furthermore, the collaboration with Allergan reinforces CollPlant's credibility and increases its visibility in the competitive aesthetics market.
However, potential investors should also remain cautious. CollPlant has historically faced financial challenges, including the need for additional capital. The competitive landscape in regenerative medicine continues to evolve, and the company's ability to maintain its technological edge will be paramount. Monitoring regulatory developments and the broader economic conditions that could impact sales will be key.
In summary, while CollPlant's expansion of Vergenix™ STR distribution marks a promising venture with substantial growth prospects, careful consideration of financial stability and market conditions is advised for potential investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
REHOVOT, Israel , Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or ' CollPlant ' , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its European distribution network for Vergenix ™ STR through the signing of a new agreement in Poland . Vergenix ™ STR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons.
Vergenix ™ STR is a soft tissue repair matrix specifically designed for combination with platelet-rich plasma (PRP). Upon mixing, it forms a scaffold with delayed degradation and strong retention at the injury site, supporting a localized and sustained therapeutic effect. The product is intended to promote tendon healing across multiple indications, including lateral epicondylitis ( ' tennis elbow ' ), rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs.
Yehiel Tal , Chief Executive Officer of CollPlant, commented: "As we expand our distribution network across Europe and the Asia-Pacific region, we are excited about the significant market potential for Vergenix ™ STR. The product provides a differentiated treatment for tendon injuries by forming a gel matrix that enables localized, sustained release of growth factors at the injury site, thereby supporting optimal healing. We expect to deliver the first shipment to our distributor by the end of this year and look forward to further broadening our global distribution network for Vergenix ™ STR in additional territories."
About Vergenix STR
VergenixSTR is a soft tissue repair matrix that combines cross-linked rhCollagen with Platelet-rich plasma, or PRP, a concentrated blood plasma that contains high levels of platelets, a critical component of the healing process. Platelets contain growth factors that are responsible for stimulating tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation of the wound healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product is injected into the affected area and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon injury site, holding the platelet concentrate in place at the injured area. The matrix formed has the capabilities to activate the platelets in PRP, thereby releasing growth factors in a controlled manner and controlled biodegradation time, enabling optimal healing.
About CollPlant Biotechnologies
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future such as expectations regarding the market potential of VergenixSTR. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results, including with respect to the Company's dermal filler product; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers and the ability to manufacture and supply its products to cover market demands; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel , projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2772688/COLLPLANT_VergenixSTR.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
SOURCE CollPlant
FAQ**
How does the expansion of Collplant Holdings CQPTY’s distribution network for VergenixSTR in Europe enhance its market reach and impact on treating tendon injuries?
What are the expected financial implications for Collplant Holdings CQPTY as a result of the new distribution agreement in Poland for VergenixSTR?
In what ways does VergenixSTR's design with platelet-rich plasma differentiate it from competing products, and how could this benefit Collplant Holdings CQPTY in the European market?
What strategies does Collplant Holdings CQPTY have in place to ensure successful implementation of this agreement and to address potential risks associated with the expansion?
**MWN-AI FAQ is based on asking OpenAI questions about CollPlant Holdings Ltd. (NASDAQ: CLGN).
NASDAQ: CLGN
CLGN Trading
-0.8% G/L:
$0.62 Last:
15,561 Volume:
$0.60 Open:
